TVGN TEVOGEN BIO HOLDINGS INC

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them in brokerage accounts.

A DRS account is an alternative to using a brokerage account and Tevogen encourages shareholders to explore the differences. DRS accounts ensure your shares are registered directly in your name and not held through intermediary brokers, allowing shareholder to exercise direct control over their shares. DRS accounts may also have reduced transaction and account maintenance costs for shareholders. Brokerage accounts may provide greater access to tools, and selling shares in this type of account may be quicker when compared to a DRS account. Investors may also incur certain costs in connection with transferring shares in and out of a brokerage account.

For more information about these and other differences, please contact the Company’s transfer agent, Continental Stock Transfer & Trust.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Sup...

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas. Computer-based selection of EBV peptides is currently underway as part of Tevogen’s preparation for a potential clinical trial using EBV-specific CTLs manufactured using the Company’s proprietary ExacTcell™ technology. ExacTcell...

 PRESS RELEASE

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimil...

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand. An update on AI and other Company assets, to have a market value of $10 billion, is forthcoming.Shareholders will soon receive an update on Tevogen’s goal of finalizing in-house manufacturing capabilities, which are expected to support projected cumulative revenues of $10–14 billion for Tevogen Onco...

 PRESS RELEASE

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Pr...

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening ...

 PRESS RELEASE

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patient...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. , the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expan...

 PRESS RELEASE

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Part...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch